4.3. Analysis.
Comparison 4: Topotecan versus Topotecan/thalidomide, Outcome 3: Toxicity(2)
| Toxicity(2) | |||||
| Study | Toxicity | TopotecanGrade 1, 2 n(%) | TopotecanGrade 3, 4 n(%) | Topotecan/thalidomideGrade 1, 2 n(%) | Topotecan/thalidomideGrade 3, 4 n(%) |
| Downs 2008 | Hemorrhage | 1(3) | 0 | 0 | 0 |
| Infection | 0 | 3(8) | 2(7) | 2(7) | |
| Febrile neutropenia | 0 | 4(10) | 0 | 2(7) | |
| Lymphatics | 1(3) | 0 | 1(3) | 0 | |
| Metabolic | 1(3) | 1(3) | 1(3) | 0 | |
| Musculoskeletal | 3(8) | 0 | 3(10) | 0 | |
| Neurologic | 4(10) | 0 | 7(23) | 4(13) | |
| Peripheral neurophathy | 2(5) | 0 | 4(13) | 0 | |
| Ocular/visual | 2(5) | 0 | 2(7) | 1(3) | |
| Pain | 8(21) | 2(5) | 8(27) | 0 | |